Chat with Client Services
Site Search
Dr. Gwen McMillin says ARUP's new therapeutic drug monitoring (TDM) for imatinib has definite patient benefits.
It is silent, but sometimes present. When exposed, a child can be anemic or hyperactive, have a lower IQ or even hearing problems.
Adverse drug reactions cause more than 700,000 ER visits each year, with some 120,000 patients needing to be hospitalized for further treatment, according to the CDC.
